Allegretti, Marcello http://orcid.org/0000-0002-0617-0233
Cesta, Maria Candida http://orcid.org/0000-0002-4847-2985
Zippoli, Mara
Beccari, Andrea
Talarico, Carmine
Mantelli, Flavio
Bucci, Enrico M. http://orcid.org/0000-0002-3317-8003
Scorzolini, Laura
Nicastri, Emanuele
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (101003551 - Exscalate4CoV, 101003551, 101003551, 101003551, 101003551, 101003551)
Ministero della Salute (12371675, 12371675)
Article History
Received: 25 January 2021
Revised: 9 July 2021
Accepted: 25 July 2021
First Online: 17 August 2021
Competing interests
: MA, MCC, MZ, AB, CT, and FM are permanent employees of Dompé Farmaceutici S.p.A, coordinator of the Horizon 2020 European project “N.101003551-EXSCALATE4CoV” and sponsor of the running clinical trial conducted with raloxifene on COVID-19 patients. EN and LS are employees of Lazzaro Spallanzani National Institute for Infectious Disease, IRCCS, Rome. EMB declares no conflict of interest.